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Abstract
 Candida and Aspergillus, are two important fungi that can cause systemic or invasive mycoses in human. Micafungin 
is an antifungal agent belongs to echinocandin group with antifungal activity against Candida and Aspergillus. In this 
study in vitro activity of micafungin against Candida and Aspergillus, and in vivo activity to Candida parapsilosis 
were presented. A study on the in-vitro activity of micafungin for Candida and Aspergillus was conducted at our 
laboratory in August-September 2010. We used E-test on Mueller Hinton agar supplemented by 2% glucose and 
methylen blue as indicator. The strains tested were isolated from blood, bronchial lavage, urine, stool and skin. 
Candida albicans (ATCC 90028), and Candida parapsilosis (ATCC 22019) were use for quality control of the 
experiments. The minimum inhibitory concentration (MIC) was read at 24-48 hours after incubation for Candida 
and 48 hours for Aspergillus. According to MIC the response to micafungin was determined as susceptible (S), 
susceptible dose dependent (SDD)/ intermediate and resistant (R). Quality control was done in the same method. 
To support the laboratory work we present an in vivo activity of micafungin as  a case report of C. parapsilosis 
candidemia. All Candida and Aspergillus isolates were within the range of susceptible. From Candida group, C. 
parapsilosis  even though susceptible but shows the highest MIC (0.75 – 1.5). Aspergillus niger showed highest 
MIC (0.32), and the most frequent causative agent of aspergillosis Aspergillus fumigatus shows low MIC value. The 
result of quality control is within expected range.   Micafungin shows a good antifungal activity to all Candida and 
Aspergillus Jakarta isolates. In vivo activity of micafungin against C. paraspilosis is inline with the in-vitro result. 
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Mikafungin: Aktivitas In-vitro terhadap Candida dan Aspergillus dan Aktivitas In-vivo 
terhadap Candida parapsilosis
Abstrak
Candida dan Aspergillus, adalah dua jamur penting penyebab mikosis invasif atau sistemik pada manusia. Mikafungin 
diketahui sebagai antijamur golongan echinocandin yang mampu mengeliminasi Candida dan Aspergillus. Dalam 
penelitian ini kami ingin meneliti kemampuan in vitro mikafungin terhadap Candida dan Aspergillus, serta 
menyampaikan laporan kasus aktivitas in vivo mikafungin terhadap  Candida parapsilosis. Studi untuk mengetahui 
aktivitas invitro dari mikafungin terhadap Candida dan Aspergillus, dilakukan di laboratorium mikologi departemen 
Parasitologi FKUI pada bulan Agustus-September 2010. Kami menggunakan E-test pada media agar Mueller Hinton 
dengan indikator glukosa 2% dan metilen biru. Strain yang kami periksa diisolasi dari darah, cairan bronkial, urin, 
tinja dan kulit. Sebagai kontrol kualitas uji kepekaan, kami gunakan Candida albicans (ATCC 90028), dan Candida 
parapsilosis (ATCC 22019). Konsentrasi hambat minimal (KHM) dibaca setelah inkubasi 24-48 jam untuk Candida 
dan 48 jam untuk Aspergillus. Respons terhadap mikafungin dibaca sebagai susceptible (S), susceptible dose 
dependent (SDD) / intermediate and resistant (R). Kontrol kualitas uji kepekaan juga dibaca dengan metode yang 
sama. Guna memperkuat hasil laboratorium, kami laporkan aktivitas in vivo mikafungin terhadap C. parapsilosis 
pada kasus kandidemia. Seluruh isolat Candida dan Aspergillus sensitif terhadap mikafungin. Dari golongan 
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Candida, C. parapsilosis walaupun masih sensitif namun menunjukkan KHM tertinggi (0,75 - 1,5).  Aspergillus 
niger menunjukkan KHM tertinggi (0,32), dan strain Aspergillus fumigatus sebagai penyebab tersering aspergillosis 
menunjukkan nilai KHM rendah.  Aktivitas Mikafungin bagus sebagai antijamur terhadap semua strain Candida 
dan Aspergillus di Jakarta. Aktivitas in vivo mikafungin terhadap C. paraspilosis sesuai dengan in-vitro.
Kata kunci: Candida, Aspergillus, neonatus, kandidemia
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Introduction
Candida and Aspergillus, are two 
important fungi that can cause systemic 
or invasive mycoses in human. Invasive 
mycoses is a life threatening infection, 
and to overcome the infection appropriate 
antifungal is needed.1,2 
Micafungin is an antifungal agent 
belongs to echinocandin group with 
antifungal activity against Candida and 
Aspergillus. The mechanism of action is 
by inhibition of (1-3)-β-D-glucan synthase 
an enzyme necessary for the production of 
(1-3)-β-D-glucan an integral part of fungal 
cell wall.3 Currently, in some countries 
micafungin was approved for the treatment 
of invasive infection caused by Candida 
and Aspergillus both in adult and pediatric 
patients.4 In Indonesia micafungin was 
already use for several years, but the data on 
susceptibility pattern of Indonesian strains 
to micafungin is not available. 
In this study we would like to present 
a preliminary report on the susceptibilitiy 
pattern of Candida and Aspergillus of Jakarta 
strains against  micafungin. In vivo activity 
of micafungin to Candida parapsilosis which 
is known less susceptible to micafungin, will 
be presented as case report. 
 
Material and Methods
Susceptibility study
Isolates 
All isolates used in this study 
are collection of Mycology Division, 
Department of Parasitology, Universitas 
Indonesia, Faculty of Medicine. A panel 
consisiting of 23 clinical isolates belonging 
to 23 different Candida strains were tested. 
Each  isolates was obtained from a various 
clinical specimens which was sent to our 
laboratory for diagnosis, identification and 
susceptibility testing. The clinical specimens 
from which the fungi isolated were  blood, 
bronchial lavage, urine, stool and skin. The 
Candida isolates tested consist of  seven 
isolates of C. albicans,  one  isolate of C. 
glabrata, C. parapsilosis, (three isolates), 
C. tropicalis (five  isolates), C. krusei (two 
isolates) dan C. kefyr (five isolates). 
For Aspergillus  a panel consist of  one 
isolate of A. niger,  two isolates of A. flavus 
and two isolates of  A. fumigatus  were tested. 
Each strain was obtainned from different 
clinical materials such as tumor biopsy, skin 
biopsy and sputum. 
Candida albicans (ATCC 90028), and C. 
parapsilosis (ATCC 22019) were included 
as quality control in the experiments. 
Inocculum Preparation 
 
The isolates were refreshed by re-
culture on sabouraud dextrose agar (SDA). 
For Candida incubation period was 24 
hour, while for Aspergillus due to its 
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where the elliptical inhibition zone intersect 
with the scale on the strip. The interpretation 
of their susceptibility pattern is based on the 
susceptibility breakpoint.7-9 Quality control 
with C. albicans (ATCC 90028) , and C. 
parapsilosis (ATCC 22019) was done by the 
same method. 
Case Report 
In completion of susceptibility study, a 
case report on an invasive infection caused 
by C. parapsilosis will be presented. 
Results
Susceptibility Study
As summarized in Table 1, a total of 
23 isolates of Candida and five isolates of 
Aspergillus were tested. The isolates were 
obtained from various clinical materials 
and for Candida mostly were derived from 
blood whereas the origin of Aspergillus is 
distributed from sputum, bronchial lavage, 
and tissue biopsy. 
maturation of sporulation, the incubation 
period was a week. Both were incubated at 
room temperature (29°C). After incubation, 
the fungi were harvested and the spores 
were suspended into sterile distilled 
water then adjusted until the final 
concentration equivalent to 0.5 McFarland 
turbidity standard and used for susceptibility 
test
Susceptibility Testing
Susceptibility was conducted by using 
E-test strip  for micafungin (AB-BIODISK, 
Solna Sweden), on Müeller Hinton agar 
supplemented by 2% glucose and  0.5µg/ml 
methylene blue as indicator.5-6 Using a sterile 
cotton swab the suspension was rubbed 
carefully onto the surface of Müeller-Hinton 
agar, and lets 15 minutes for the liquid to seep 
into the medium before addition of E-test 
strip, then incubated at 35° C. For Candida. 
Results were read at 24 and 48 hours after 
incubation whereas for  Aspergillus  after 48 
hours. 
The minimum inhibitory concentration 
(MIC) was determined on the concentration 
Table 1: The Origin of Isolates Used in Susceptibility Study
clinical materials
isolates blood bronchial urine stool skin biopsy
washing
Candida spp
C. albicans 4 3 – – – –
C. tropicalis 4 – 1 – – –
C. parapsilosis 2 – – – 1 –
*C. glabrata – – – – – –
C. kefyr 5 – – – – –
C. krusei – 1 – 1 – –
Aspergillus spp.
A. fumigatus – 1 (sputum) – – – 1
A. flavus – – – –   1* 1
A. niger – – – – 1 –
* not known; A. flavus from the skin was obtained by touch biopsy; 
The results of susceptibility study  is summarized in Table 2, as MIC and result of  quality control 
using C. albicans (ATCC 90028), and C. parapsilosis (ATCC 22019), is  within the expected 
range. 
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Table 2. Results of Susceptibility Test of Candida spp. And  Aspergillus spp.  
Against Micafungin.
isolates                          n                  S        SDD  R  MIC – range 
         (total)                 µg/ml 
C. albicans  7 7   –   –  0.016 – 0.25
C. tropicalis  5 5   –  –  0.014 – 0.25
           *C. parapsilosis                    3             2    –                               0.75 – 1.5
C. krusei  2 2   –  –  0.064 – 0.094
             C. glabrata  1 1   –  –  0.0175
 C.  kefyr                5 5   –  –  0.094 – 0.38
 A.  niger                1 1   –  –  0.32
 A. fumigatus  2 2   –  –  0.006-0.047
A. flavus                2 2             –  –  0.002-0.003
Total    28 28   0  0
*one strain is not growing well; S, susceptible; SDDS, susceptible dose dependent; R, resistant; MIC, minimum 
inhibitory concentration.  
All Candida isolates tested are 
susceptible and C. parapsilosis showed 
the highest MIC  (0.75 – 1.5µ ml) but still 
in a the range of susceptible. Candida 
parapsilosis grows slowly and the result 
can only be read  after 48 hours of 
incubation period. Three isolates of 
C. parapsilosis including one quality control 
(C. parapsilosis ATCC  2201), two of 
which managed to be read after 48 hours 
of incubation, whereas one isolate could not 
be assessed because there was absolutely 
no growth. 
All of filamentous fungi were susceptible 
to micafungin and A. niger showed highest 
MIC (0.32), while A. fumigatus and A. flavus 
were susceptible in low concentration. 
In Vivo Activity Of Micafungin Against C. 
parapsilosis (Case Report)
A seven days old neonate was reffered 
to the hospital, suspected of sepsis and 
respiratory distress. His gestation period 
was 41 weeks. During pregnancy, her 
mother was admitted to the hospital when 
her pregnancy was ca. 32 weeks because of 
oligo-hydramnion. He was born by caesarean 
section with oligo-hydramnion as the 
indication, APGAR score 2/7, body weight 
is 2700 g; height is 48 cm; circumference 
of head is 33 cm and no congenital 
abnormalities were recognized. During 
pregnancy his mother was not smoking, no 
alcohol consumption, not a drug user and 
did not take jamu (Indonesian herbs) as 
supplementary. On admission, a severely ill 
neonate, dyspnea (using O2, 2L/ minute and 
saturation 59%), with unstable temperature, 
heart rate is 158/min, respiratory rate  60/min, 
epigastric retraction present, multi organ 
dysfunction, electrolyte imbalance, his body 
weight was 2454g and there was decrease 
of consciousness. The hematology data 
are: Blood: Hemaglobin 15; Hematocryte 
44.3; Leucocyte 9 430; Thrombocyte  10 
000; CRP: 121, Prothrombin time 19.9; 
albumine 2.20; blood culture: Enterobacter 
gergoviae,that susceptible to  meropenem; 
Glucose  68 mg/dl; electrolytes imbalance 
(Sodium 122, Potassium 6.60, Chloride 96); 
APTT 35.5; Calcium 1.02; pH 7.39;  PCO2 
35.0; PO2 65; Base excess 3.9; TCO2 21.5; 
HCO3 20.4; O2. Saturation 94; IT ratio 0.11. 
The emergency condition was handled and 
he was sent to neonates intensive care unit 
(NICU).  During his stay in NICU, nutrition 
was given via deep vein catheter on his right 
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times blood culture positive, one before 
and one during treatment and temperature 
always above 37°C). During micafungin 
treatment liver function returned to normal, 
patient was able to have treatment orally and 
hemodynamically stable). 
Discussion
Isolates tested were obtained from 
various clinical materials. Candida strains 
mostly isolated from blood and other body 
parts (Table 1). In human body, digestive 
tract, respiratory tract, and sometimes skin 
are known as the sites where Candida lives 
as saprophyte. But, in certain condition 
such as alteration of micro-environmental 
balance due to many causes, they are able to 
cause invasive infection, and candidemia is 
the most frequent clinical manifestation.10-11 
Thus, we used the strains isolated from 
blood and also from other sites represent the 
source of  infection. Nucci and Annaisie10 
analysed 21 papers on the association 
of candidemia and its possible source of 
infection. They ended on conclusion that 
the major source of infection is colonization 
of Candida in the gut. Whereas for C. 
paraspilosis infection mostly originated 
from skin colonization especially patients 
who use deep vein/central venous catheter 
as happened in this patient.  
In our study (Tabel 2), all Candida 
strains tested were within the range of 
susceptible to micafungin. The highest MIC 
was shown by C. parapsilosis (MIC range is 
0.75 – 1.5µg/ml). This result was generally 
consistent with the result of other studies.7, 12-
14 Pfaler et al conducted a global surveilance 
for in vitro activity of micafungin and 
caspofungin. They find out that C. albicans, 
C. tropicalis, C. kefyr, C. glabrata,  and C. 
krusei  were belong to the group of  highly 
susceptible, while C. parapsilosis was 
less susceptible.14 Candida krusei known 
as intrinsically resistent to fluconozale, 
groin. He was given 2x75mg meropenem 
with a good response, but his temperature 
was always a little bit above 37°C; amikacin 
2x15 mg was added and the temperature 
became normal (< 37°C)  and the baby is 
more active, and able to take nutrition orally. 
Antibiotics were planned to be given for 21 
days but, on the day 12  there was an increase 
of temperature (38.8°C) and a second blood 
culture was taken. While waiting for the 
laboratory results mycostatin was given to 
prevent translocation of Candida from the 
bowel system. The result of blood culture is C. 
parapsilosis and the diagnosis of candidemia 
caused by   C. parapsilosis was established. 
Antifungal agent was considered and we 
checked liver and renal function to choose 
suitable antifungal agent. Amphotericin B 
was not given because of the decrease of 
renal function (blood urea 172.5 & creatinine 
1.5); azole derivatives did not come in to 
consideration because there were increased 
of ALT/SGOT and AST/SGPT (350 & 281). 
Based on the condition of both renal and 
liver function,  micafungin was chosen. In 
addition, the patient was hemodynamically 
unstable. Then all antibiotics were stopped 
and micafungin was started with the dose 2 
mg/ kgBW/ day (according to monograph 
released by Astellas), diluted in saline and 
given for 12 days. On the day-3 of treatment 
another blood culture was conducted and 
again C. parapsilosis was isolated; the 
diagnosis is proven candidemia caused by 
C. parapsilosis. The use of micafungin 
improved patient’s condition, clinically the 
patient was getting better but his temperature 
was still around 37°C with some spikes, 
maximum 38.2°C at the day-3 of treatment. 
During micafungin treatment liver and renal 
function were returned to normal (ALT 
from 350 to 40 and AST from 281to 38.8). 
On the day 13 micafungin was replaced 
by fluconazole orally (12 mg/day) for 14 
days. The reason to give fluconazole were 
persistent C. parapsilosis infection (two 
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within the range of susceptible with the 
highest MIC is A. niger (0.32µg/ml). This 
result is consistent to Watanabe et al., 
20 that micafungin has killing activity to 
Aspergillus. 
Aspergillosis, an infection caused 
by Aspergillus associated with wide 
clinical spectrum, among others invasive 
aspergillosis a lethal sino-pulmonary 
infection. Invasive aspergillosis is a disease 
in compromised individual e.g. as patients 
with hematology malignancy, patients 
admitted to the intensive care and patient 
under steroid treatment. Without proper 
treatment the disease can be fatal.21 This 
study is a preliminary study with limited 
number of strains. So, it has not been able 
to have   a complete susceptibility pattern of 
Candida and Aspergillus against micafungin 
and it is limitations of our study. 
According to this result micafungin 
Aspergillus and Candida used in this study 
were susceptible to micafungin and can be 
used for the treatment of invasive candidasis 
and invasive aspergillosis.
 In Indonesia, antifungal armamentarium 
are quite limited, even for such a grave 
infection as invasive fungal infection, only 
amphotericin B and azoles derivatives 
(fluconazole and voriconazole) are available. 
Thus, the availability of echinocandin group 
in this case micafungin  which has different 
mechanism with azole and poly-en will be 
beneficial.
In this case we choose micafungin 
because of patient condition that did not 
permit the use of azole derivatives such 
as fluconazole. We have to be careful with 
the increasing number of C. parapsilosis 
infection due caspofungin usage,22 although 
other (Le Pera et al 2011-Asbtract) 
mentioned that C. parapsilosis can be 
eradicated in the C. parapsilosis break 
through infection during fluconazole 
prophylaxis.23  
a widely use antifungal agent, while C. 
glabrata is less sensitive to fluconazole,15 
but in our study both fungi show low MIC 
which is in line with high eficacy. Further 
more, C. albicans, and C. tropicalis are the 
most common causes of Candida invasive 
infection in Jakarta2 and  were susceptible to 
micafungin.   
Our in vitro study showed a less activity 
against C. parapsilosis, it needs longer 
time to show its efficacy and the result 
showed highest MIC compare with other 
species. Other studies conducted in Italy13 
also support our finding, and even rare, the 
development of resistant to micafungin is 
more likely to occur in C. parapsilosis.16-17 
Candida parapsilosis is unusual cause for 
candidemia and known as less susceptible to 
micafungin.7
Our result on in-vitro study confirmed 
by in vivo observation in a neonate who 
suffered invasive candidiasis caused by C. 
parapsilosis. This drug is not really potent for 
C. parapsilosis, but only inhibit the growth 
of fungi. But on the other hand  micafungin 
is more safe for liver and kidney, so it could 
be used for the patients with mild-moderate 
liver and kidney dysfunction.18
Its inhibitory power of the fungus 
provides an opportunity for the homeostasis 
system to improve the functioning of both 
organs. So when both organs were returned 
to normal, anti-fungal drugs which could 
eradicate C. parapsilosis such as fluconazole 
can be given. Micafungin is also excellent 
for use in unstable homeostasis conditions. 
All of the above conditions can be found in 
the neonates reported in this report.  Dosage 
of  2 mg/ BW later on known as a small dose 
since in neonates the clearance of micafungin 
is faster then adult.19 
Filamentous fungi tested in our study is 
Aspergillus spp., consisting of A. fumigatus, 
A.  flavus and A. niger. The result showed 
that the MIC of the Aspergilli tested were 
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Conclusion 
In vitro, all the Candida and Aspergillus 
strains tested were susceptible to micafungin. 
In Candida  group C. parapsilosis showed 
the highest MIC while in the Aspergilli 
group was A. niger. In vivo, even though 
micafungin treatment in the dose 2mg/kg/
bw/day could not eradicate C. parapsilosis, 
but it restore liver and renal function, 
enable replacement by other more suitable 
antifungal agent. 
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